Wall Street is sifting data to figure out what Celldex Inc.’s phase II failure with KIT inhibitor barzolvolimab (barzo) in prurigo nodularis (PN) might mean for the upcoming phase III readout with the same drug in chronic spontaneous urticaria (CSU).